האמט פי 250iu fviii 600iu vwf
csl behring ltd., israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה\אינפוזיה - factor viii (human) 250 iu / 5 ml; von willebrand factor 600 iu / 5 ml - coagulation factor viii - coagulation factor viii - congenital and acquired deficiency of blood clotting factor viii: severe or moderate haemophilia, prophylaxis during operation, von willebrand's disease.
האמט פי 1000iu fviii 2400iu vwf
csl behring ltd., israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה\אינפוזיה - factor viii (human) 1000 iu / 15 ml; von willebrand factor 2400 iu / 15 ml - coagulation factor viii - coagulation factor viii - congenital and acquired deficiency of blood clotting factor viii: severe or moderate haemophilia,prophylaxis during operation, von willebrands disease.
האמט פי 500iu fviii 1200iu vwf
csl behring ltd., israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה\אינפוזיה - factor viii (human) 500 iu / 10 ml; von willebrand factor 1200 iu / 10 ml - coagulation factor xiii - coagulation factor xiii - congenital and acquired deficiency of blood clotting factor viii: severe or moderate haemophilia, prophylaxis during operation, von willebrands disease.
וילאט 1000
dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 1000 iu/vial; factor viii (human) 1000 iu/vial - coagulation factor viii
וילאט 500
dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 500 iu/vial; factor viii (human) 500 iu/vial - coagulation factor viii
פייבה 500 יחידות
takeda israel ltd - factor viii inhibitor bypassing fraction - אבקה וממס להכנת תמיסה להזרקה\אינפוזיה - factor viii inhibitor bypassing fraction 500 u/vial - factor viii inhibitor bypassing activity - factor viii inhibitor bypassing activity - for the control of bleeding episodes in haemophilia a patients with factor viii inhibitors and also in patients with acquired factor viii inhibitors.
פייבה 1000 יחידות
takeda israel ltd - factor viii inhibitor bypassing fraction - אבקה וממס להכנת תמיסה להזרקה\אינפוזיה - factor viii inhibitor bypassing fraction 1000 u/vial - factor viii inhibitor bypassing activity - factor viii inhibitor bypassing activity - for the control of bleeding episodes in haemophilia a patients with factor viii inhibitors and also in patients with acquired factor viii inhibitors .
פאנדי 100 יח'מל 1500 יח' (פקטור 8)
medici medical ltd, israel - factor viii (human) - אבקה להכנת תמיסה לזריקה - factor viii (human) 1500 iu/dose - factor viii inhibitor bypassing activity - factor viii inhibitor bypassing activity - is indicated for the prevention and control of bleeding in patients with moderate or severe factor viii deficiency due to classical hemophilia a . fanhdi is not effective in controlling the bleeding of patients with von willebrond's disease.
קוג'נייט fs 500 iu
bayer israel ltd - antihemophilic factor (recombinant) sucrose - אבקה להכנת תמיסה לזריקה - antihemophilic factor (recombinant) sucrose 500 iu/vial - blood coagulation factors - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor viii.routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with severe hemophilia a with no pre-existing joint damage. kogenate fs is not indicated for the treatment of von willebrand’s disease.
קוג'נייט fs 1000 iu
bayer israel ltd - antihemophilic factor (recombinant) sucrose - אבקה להכנת תמיסה לזריקה - antihemophilic factor (recombinant) sucrose 1000 iu/vial - blood coagulation factors - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor viii.routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children under with severe hemophilia a with no pre-existing joint damage.kogenate fs is not indicated for the treatment of von willebrand’s disease.